Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Post-Mkt 01-16 17:05:09 EST

2.89

-0.31

-9.69%

盘后2.95

+0.06+2.08%

17:01 EST

High3.26	Low2.88	Vol826.77K
Open3.25	D1 Closing3.20	Amplitude11.88%
Mkt Cap76.59M	Tradable Cap67.10M	Total Shares26.50M
T/O2.48M	T/O Rate3.56%	Tradable Shares23.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":2.89,"timestamp":1768597200000,"preClose":3.2,"halted":0,"volume":826772,"hourTrading":{"tag":"盘后","latestPrice":2.95,"preClose":2.89,"latestTime":"17:01 EST","volume":1401,"amount":4053.1249427999996,"timestamp":1768600917025},"delay":0,"floatShares":23219400,"shares":26502889,"eps":-1.441903,"marketStatus":"Post-Mkt","change":-0.31,"latestTime":"01-16 17:05:09 EST","open":3.25,"high":3.26,"low":2.88,"amount":2478727.1922476,"amplitude":0.11875,"askPrice":3.2,"askSize":100,"bidPrice":2.91,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-1.441903,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768611600000},"marketStatusCode":4,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":3.2,"preHourTrading":{"tag":"盘前","latestPrice":3.31,"preClose":3.2,"latestTime":"09:24 EST","volume":18,"amount":59.589999,"timestamp":1768573497779},"postHourTrading":{"tag":"盘后","latestPrice":2.95,"preClose":2.89,"latestTime":"17:01 EST","volume":1401,"amount":4053.1249427999996,"timestamp":1768600917025},"volumeRatio":1.231775,"impliedVol":0.7153,"impliedVolPercentile":0.2749},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2592184979","title":"Annovis Bio Launches 36-Month Study of Buntanetap in Parkinson's Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184979","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592184979?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:35","pubTimestamp":1766093715,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. announced plans to begin an Open-Label Extension  study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson's disease. The study aims to enroll 500 participants, including both previous Annovis clinical trial participants and patients who have been receiving deep brain stimulation  for at least 12 months. The study will monitor patients over 36 months and collect skin and plasma biomarkers to enhance understanding of disease progression. The announcement outlines future research; no specific scientific results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via Glob","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL46bhv0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014039.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","ANVS","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","BK4585"],"gpt_icon":0},{"id":"2592184980","title":"Annovis Bio Inc - to Begin Open-Label Extension Study in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592184980?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:35","pubTimestamp":1766093700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6M7P0P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2591847509","title":"Annovis Bio Inc. Hosts Corporate Update Webinar Featuring CEO Maria Maccecchini","url":"https://stock-news.laohu8.com/highlight/detail?id=2591847509","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591847509?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890032,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. will host a corporate update webinar on January 28, 2026, at 4:30 p.m. ET. The event will feature President and CEO Maria Maccecchini, Ph.D., who will provide an overview of the company's recent progress, ongoing clinical programs, and strategic direction. The webinar is open to shareholders, patients, investigators, and other interested parties, with a live Q&A session to follow the presentation. Participants are encouraged to submit questions in advance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1Tq6Wm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","BK4585","ANVS","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2591982564","title":"Annovis to Host Corporate Update Webinar on January 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982564","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982564?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Dec.  16, 2025  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neuro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206176/0/en/Annovis-to-Host-Corporate-Update-Webinar-on-January-28-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4132","BK4218","LU1169590202.USD","ANVS","BK4585","LU1169589451.USD","BK4139","HST","BK4023","AD","BK4181","PD"],"gpt_icon":0},{"id":"2590360322","title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360322","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590360322?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:05","pubTimestamp":1765242345,"startTime":"0","endTime":"0","summary":"Michael B. Hoffman, Director of Annovis Bio Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL4FctjJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2588904620","title":"Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588904620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588904620?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766846,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. will present at the 2025 Annual Meeting of the Parkinson Study Group, taking place from December 4-6, 2025, in San Diego, California. The company will showcase new data on buntanetap's effects in Parkinson's disease dementia patients, focusing on cognitive outcomes and biomarker improvements, with a poster guided tour led by President and CEO Maria Maccecchini scheduled for December 5 at 6:15 p.m. PST.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2hByHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","ANVS","BK4139","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2586410289","title":"Director Makes Bold Move with Major Annovis Bio Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2586410289","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586410289?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:11","pubTimestamp":1764123106,"startTime":"0","endTime":"0","summary":"New insider activity at Annovis Bio ( ($ANVS) ) has taken place on November 25, 2025. Director Michael B. Hoffman recently made a significant inves...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-annovis-bio-stock-purchase-insider-trading-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-annovis-bio-stock-purchase-insider-trading-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2586050470","title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586050470","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586050470?lang=en_us&edition=fundamental","pubTime":"2025-11-26 01:27","pubTimestamp":1764091646,"startTime":"0","endTime":"0","summary":"Michael B. Hoffman, Director of Annovis Bio Inc., reported an acquisition of common shares of Annovis Bio Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLTnH1j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2585462544","title":"Annovis Bio Unveils New Clinical Data on Buntanetap at CTAD 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462544?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989241,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. has announced two upcoming presentations at the 18th Clinical Trials on Alzheimer's Disease  conference, scheduled for December 1-4, 2025, in San Diego, California. The first presentation will address amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson's disease dementia patients. The second presentation will discuss a double 6/18-month Phase 3 study designed to evaluate the symptomatic and potential disease-modifying efficacy of buntanetap in treating Alzheimer's disease. The results from these studies will be presented at the CTAD conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on Nove","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL9hlkDs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU2210149790.SGD","BK4588","IE00B64PRP62.GBP","ANVS","BK4139","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2585122005","title":"Annovis Bio Inc. Director Michael B. Hoffman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585122005","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585122005?lang=en_us&edition=fundamental","pubTime":"2025-11-22 08:58","pubTimestamp":1763773091,"startTime":"0","endTime":"0","summary":"Michael B. Hoffman, Director at Annovis Bio Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251122:nNDL385LfK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Inc. Director Michael B. Hoffman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2584597859","title":"Annovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2584597859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584597859?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:15","pubTimestamp":1763579727,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Annovis Bio and keeping the price target at $8.00. Jason McCarthy has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/annovis-bio-receives-buy-rating-amid-promising-phase-3-trial-results-and-strategic-fda-discussions-for-buntanetap-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/annovis-bio-receives-buy-rating-amid-promising-phase-3-trial-results-and-strategic-fda-discussions-for-buntanetap-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"gpt_icon":0},{"id":"2584232995","title":"Director Makes Bold Move with Major Annovis Bio Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2584232995","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584232995?lang=en_us&edition=fundamental","pubTime":"2025-11-19 10:10","pubTimestamp":1763518242,"startTime":"0","endTime":"0","summary":"New insider activity at Annovis Bio ( ($ANVS) ) has taken place on November 18, 2025. Director Michael B. Hoffman recently made a significant inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-annovis-bio-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-annovis-bio-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2584552589","title":"Annovis announces FDA meeting to discuss PDD program","url":"https://stock-news.laohu8.com/highlight/detail?id=2584552589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584552589?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:39","pubTimestamp":1763476785,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced that the U.S. Food and Drug Administration, FDA, has scheduled a Type C meeting in January 2026 to discuss the Company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-announces-fda-meeting-to-discuss-pdd-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-announces-fda-meeting-to-discuss-pdd-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2039709279.SGD","LU0047713382.USD","IE00B29SXG58.USD","LU2087589342.USD","LU0456827905.SGD","LU2242644610.SGD","LU0594300419.USD","LU1719994722.HKD","LU1720050803.USD","IE0034224299.USD","LU0605514214.HKD","LU1064131342.USD","LU0878005551.USD","LU1048588211.SGD","BK4503","LU0455707207.USD","BK4505","LU0823038988.USD","BK4509","LU0348805143.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU1769817096.USD","LU1868838027.USD","LU0329678170.USD","LU0072462343.USD","BK4501","LU0117841782.USD","BK4588","LU1956131251.USD","BK4504","SG9999002562.SGD","LU0307460666.USD","LU0231483743.USD","LU1988902786.USD","LU0048580855.USD","LU1769817179.HKD","LU0329678337.USD","LU0823039010.USD","LU1251922891.USD","LU0315179316.USD","LU0359201885.HKD","LU1235295612.USD","LU0235996351.USD","LU1770034418.SGD","BK4558","ANVS","LU0359201612.USD","LU0348788117.USD"],"gpt_icon":0},{"id":"2584519930","title":"BRIEF-Annovis Announces FDA Meeting To Discuss Parkinson's Disease Dementia Program Reaffirms FDA Alignment On Pivotal Phase 3 Alzheimer's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584519930","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584519930?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:17","pubTimestamp":1763471865,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Announces FDA Meeting To Discuss Parkinson's Disease Dementia Program Reaffirms FDA Alignment On Pivotal Phase 3 Alzheimer's Disease StudyAnnovis Bio Inc ANVS.N:ANNOVIS ANNOUNCES FDA MEE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA9LWBT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2584937903","title":"Annovis Bio Inc - Announces FDA Type C Meeting for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937903?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:00","pubTimestamp":1763470808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA9LWBT3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2584378639","title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584378639","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584378639?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:44","pubTimestamp":1763469873,"startTime":"0","endTime":"0","summary":"Michael B. Hoffman, Director at Annovis Bio Inc., reported the acquisition of common shares of Annovis Bio Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL3wnfJw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2584726675","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2584726675","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584726675?lang=en_us&edition=fundamental","pubTime":"2025-11-18 02:57","pubTimestamp":1763405837,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) said Monday its phase 3 trial evaluating Ziihera plus chemotherapy as a first-line treatment in gastroesophageal adenocarcinoma showed a statistically significant improvement in progr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","BK4139","ANVS","BK4007","ZYME","IE00BN0W2V16.EUR","LU0889565916.HKD","IE00BN0W2W23.USD","LU0109394709.USD","LU0320765992.SGD","JAZZ","BK4532","LU0823416689.USD","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2584689673","title":"Annovis Bio Shares Rise After Positive Trial Data for Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2584689673","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584689673?lang=en_us&edition=fundamental","pubTime":"2025-11-18 01:43","pubTimestamp":1763401380,"startTime":"0","endTime":"0","summary":"Annovis Bio shares were 43% higher, at $3.33, after the company reported positive results from a Phase 3 trial for buntanetap.The late-stage clinical drug-platform company on Monday said the new data demonstrated a positive impact of amyloid copathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap.The Malvern, Pa., company said that in its Phase 3 study in early Parkinson's patients, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia.Further analysis revealed that about 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which Annovis said was counteracted and reversed by buntanetap.Buntanetap treatment also led to significant cognitive improvement in Parkinson's patients with amyloid copathology.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Shares Rise After Positive Trial Data for Buntanetap","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2584698625","title":"BRIEF-Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology To Accelerated Cognitive Decline In Parkinson's Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2584698625","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584698625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:04","pubTimestamp":1763384691,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology To Accelerated Cognitive Decline In Parkinson's PatientsAnnovis Bio Inc ANVS.N:ANNOVIS REPORTS NEW BIOMARKER DATA LINKING AMYLOID ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA9K57LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2584625304","title":"Annovis Bio Inc - Buntanetap Improves Cognition in Parkinson's With Amyloid Co-Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625304","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625304?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA9K57LS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.1837},{"period":"1month","weight":-0.1858},{"period":"3month","weight":0.6162},{"period":"6month","weight":0.2075},{"period":"1year","weight":-0.3361},{"period":"ytd","weight":-0.0751}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.016574},{"month":2,"riseRate":0.333333,"avgChangeRate":0.070008},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.037484},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.134852},{"month":5,"riseRate":0.666667,"avgChangeRate":0.302491},{"month":6,"riseRate":0.5,"avgChangeRate":0.167707},{"month":7,"riseRate":0.666667,"avgChangeRate":0.098191},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070358},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction